

Supplementary data

Table 1 Seropositivity rates and GMTs for serum anti-HPV-16 and anti-HPV-18 type-specific antibodies measured by ELISA at Month 60 in ATP and TVC cohorts.

ATP cohort for immunogenicity, seronegative and DNA-negative prior to vaccination							
Age	Antigen	HPV-16/18 vaccine			HPV-6/11/16/18 vaccine		
		N	% SP [95% CI]	GMT [95% CI]	N	% SP [95% CI]	GMT [95% CI]
18–26 y							
	HPV-16	31	100 [88.8, 100]	1197 [830, 1725]	35	100 [90.0, 100]	232 [154, 350]
	HPV-18	31	100 [88.8, 100]	452 [282, 725]	40	95.0 [83.1, 99.4]	49.6 [33.0, 74.6]
27–35 y							
	HPV-16	28	100 [87.7, 100]	603 [428, 849]	20	100 [83.2, 100]	156 [100, 242]
	HPV-18	39	100 [91.0, 100]	232 [184, 293]	26	88.5 [69.8, 97.6]	30.9 [19.0, 50.3]
36–45 y							
	HPV-16	31	100 [88.8, 100]	430 [300, 617]	31	100 [88.8, 100]	199 [146, 272]
	HPV-18	39	100 [91.0, 100]	242 [170, 345]	43	95.3 [84.2, 99.4]	41.0 [30.5, 55.0]
TVC, irrespective of serostatus and DNA status prior to vaccination							
Age	Antigen	HPV-16/18 vaccine			HPV-6/11/16/18 vaccine		
		N	% SP [95% CI]	GMT [95% CI]	N	% SP [95% CI]	GMT [95% CI]
18–26 y							
	HPV-16	62	100 [94.2, 100]	1143 [886, 1473]	65	100 [94.5, 100]	324 [239, 438]
	HPV-18	62	100 [94.2, 100]	423 [314, 571]	65	96.9 [89.3, 99.6]	52.8 [38.7, 71.9]
27–35 y							
	HPV-16	76	100 [95.3, 100]	840 [675, 1045]	60	100 [94.0, 100]	313 [230, 427]

	HPV-18	76	100 [95.3, 100]	326 [262, 405]	60	95.0 [86.1, 99.0]	56.6 [39.2, 81.9]
36–45 y							
	HPV-16	75	100 [95.2, 100]	837 [613, 1142]	82	100 [95.6, 100]	448 [332, 605]
	HPV-18	75	100 [95.2, 100]	292 [222, 385]	82	97.6 [91.5, 99.7]	75.6 [55.5, 103]

95% CI, exact 95% confidence interval; GMT, geometric mean titer; N, number of subjects with available results; ELISA, enzyme-linked immunosorbent assay; ATP, according-to-protocol; TVC, total vaccinated cohort; SP, seropositivity (defined as IgG antibody titer ≥ 8 ELISA units/mL for HPV-16 and ≥ 7 ELISA units/mL for HPV-18; y, year.